Viking Therapeutics (VKTX) Raises Fresh Capital After Wider Losses, Is It Still Undervalued?
Viking Therapeutics (VKTX) is back in focus after reporting wider second quarter losses alongside a series of at the market equity offerings and a new universal shelf registration that increase its funding flexibility.
See our latest analysis for Viking Therapeutics.
Viking Therapeutics' share price has eased in the short term, with a 30 day share price return down 21%, while the 3 year total shareholder return of about 124% and 5 year total shareholder return above 7x show a very strong longer term move. Investors are now reassessing this performance in light of wider losses and fresh equity issuance.
If funding rounds and biotech risk are on your mind, it can help to compare Viking Therapeutics with other health focused AI opportunities using the 42 healthcare AI stocks.
After a sharp pullback, wider losses and fresh Viking Therapeutics share issuance now sit on the other side of those strong multi year returns. Does the current valuation still leave enough upside to justify the extra risk?
Most Popular Narrative: 64.1% Undervalued
The most followed valuation narrative places Viking Therapeutics' fair value at $92.72, well above the last close at $33.30. This sets up an ambitious earnings story.
Parallel development of subcutaneous and oral formulations of the same GLP-1 and GIP co agonist, including plans to start Phase III oral trials and an oral maintenance strategy, directly responds to rising patient interest in flexible obesity treatment options and could support broader market reach and future earnings growth.
Want to see what kind of revenue ramp and profit margin shift would need to back that $92 plus fair value for Viking Therapeutics? The narrative leans on long dated obesity trial outcomes, a step change in earnings power and a future valuation multiple that many investors usually associate with high growth sectors. Curious how those moving parts fit together into one price target path? The full story is in the detailed narrative.
Result: Fair Value of $92.72 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Viking Therapeutics story still hinges on successful VANQUISH obesity trials and ongoing funding needs after recent wider losses, which could challenge that bullish valuation path.
Find out about the key risks to this Viking Therapeutics narrative.
Another View: Viking Therapeutics Through A P/B Lens
There is a very different picture if you look at Viking Therapeutics using its P/B ratio instead of narrative driven fair value. VKTX trades at 9.5x book value, versus 2.5x for the US Biotechs industry and 4.6x for peers. That is a steep premium for a company that is still unprofitable. Does that premium reflect future success or stretch the risk too far?
For a closer look at how this kind of pricing stacks up against the underlying numbers, See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
The mixed tone of this Viking Therapeutics update might leave you with questions. Consider reviewing the numbers yourself and weighing the 3 important warning signs.
Looking for more investment ideas beyond Viking Therapeutics?
If Viking Therapeutics has sharpened your focus on risk and reward, do not stop here. Use the Simply Wall Street Screener to spot fresh opportunities that fit your style.
- Target potential upside with companies that combine quality fundamentals and attractive pricing by scanning the 50 high quality undervalued stocks.
- Strengthen your income stream by reviewing reliable payers through the 9 dividend fortresses.
- Dial back risk without stepping away from the market by checking the 78 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com